1-866-61-EISAI (1-866-613-4724)

Monday – Friday, 8am to 8pm ET

Patient Support

Resources to help your patients manage out-of-pocket out-of-pocket expenses for HALAVEN®, including information about the Eisai Assistance Program and the HALAVEN® Patient Assistance Program.

Eisai Assistance Program

The Eisai Assistance Program provides information to patients and healthcare professionals regarding the patient’s insurance benefits for coverage of HALAVEN® (eribulin mesylate) injection. In addition, our agents can also provide information relating to payor-specific policies for the coverage of HALAVEN®, information regarding billing and coding requirements, and answer questions regarding financial assistance options. Call the Eisai Assistance Program today for all of your billing, coding, coverage and financial assistance questions.

Contact Us

Eisai Assistance Program

Phone: 1-866-61-EISAI (1-866-613-4724)
Fax: 1-866-57-EISAI (1-866-573-4724)
Monday – Friday, 8am – 8pm ET

HALAVEN® $0 Co-Pay Program

Overview

The HALAVEN® $0 Co-Pay Program assists commercially insured HALAVEN® patients with their HALAVEN® cost-share (copayments and coinsurances). The HALAVEN® $0 Co-Pay Program provides up to $18,000 per year to assist with out-of-pocket costs for HALAVEN®.

How the Program Works

Step 1: Completed enrollment form must be submitted including both the patient's signature and the physician's signature.

Step 2: If the patient is determined to be eligible they will be sent a Welcome Letter and a card. This card should be given to your office so that it can be used to process the virtual debit card payment.

Step 3: Fax the Explanation of Benefits (EOB) or detailed Specialty Pharmacy receipt for the Halaven claim to 844-745-2350. 
The following information should be included:

  • Patient’s information including full name
  • Date of service
  • Cost of the medication
  • Amount covered by the insurance
  • Patient’s responsibility: deductible; co-payment; and co-insurance

Step 4: If the patients claim is approved, the appropriate funding based on the patient’s out of pocket costs will be loaded onto the patients' card and a confirmation letter will be sent to the patient and the provider.

Eligible commercially insured patients will pay no more than $0. Maximum benefit paid by Eisai Inc. will be $18,000 per year. Depending on your insurance plan, you could have additional financial responsibility for any amounts over Eisai's maximum liability.

For questions about the savings program, please call 1-866-61-EISAI (1-866-613-4724).

Eligibility Criteria

Good toward the purchase of HALAVEN® prescriptions. No substitutions permitted. Not available to patients enrolled in state and federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD or TRICARE. Offer available to MA residents through June 30, 2019. Offer only available to patients with private, commercial insurance. May not be combined with any other coupon, discount, prescription savings card, free trial or other offer. Federal law prohibits the selling, purchasing, trading, or counterfeiting of this card. Such activities may result in imprisonment of 10 years, fines up to $25,000, or both. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the card and complying with any other conditions imposed by insurance carriers on third-party payors. The value of this card is not contingent on any prior or future purchases. The card is solely intended to provide savings on any purchase of HALAVEN®. Use of the card for any one purchase does not obligate the patient to make future purchases of HALAVEN® or any other product. This offer will expire November 20, 2019.

HALAVEN® Patient Assistance Program

Eisai has created the HALAVEN® Patient Assistance Program for customers who need assistance paying for HALAVEN®. This program provides HALAVEN® at no cost to financially needy patients who meet program eligibility criteria.

Healthcare providers can call the HALAVEN® Patient Assistance Program at 1-866-61-EISAI (1-866-613-4724) to determine eligibility. The hours of operation are 8 AM to 8 PM ET, Monday through Friday.

Eisai reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends upon availability.

Find Information on Medicare Coverage

Learn about coverage alternatives for HALAVEN® including Medicare coverage

Dosing and Administration Questions?

Get information on dosing with HALAVEN®, including recommended dose modifications.

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

+ Expand - Collapse

Indication

HALAVEN® is a microtubule inhibitor indicated for the treatment of patients with:

  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
  • Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

HALAVEN® Important Safety Information

Warnings and Precautions

Neutropenia: Severe neutropenia (ANC < 500/mm3) lasting > 1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5 % of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4 %) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN® and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN® in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN® and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN® and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN® and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse Reactions

In patients with mBC receiving HALAVEN®, the most common adverse reactions (25%) were neutropenia (82%), anemia (58 %), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

In patients with liposarcoma and leiomyosarcoma receiving HALAVEN®, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN® were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN® were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation were fatigue and thrombocytopenia (0.9% each).

Use in Specific Populations

Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN® and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.

For more information about HALAVEN®, please see full Prescribing Information.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.

HALAVEN® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.
CORP-US0378